<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03274440</url>
  </required_header>
  <id_info>
    <org_study_id># 7405</org_study_id>
    <nct_id>NCT03274440</nct_id>
  </id_info>
  <brief_title>Effects of Marijuana on Symptoms of OCD</brief_title>
  <acronym>ECOS</acronym>
  <official_title>Effects of Marijuana on Symptoms of Obsessive-Compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot research study is to test whether certain components of the
      marijuana plant, known as &quot;cannabinoids&quot;, may help to reduce symptoms in patients with OCD.
      Specifically, patients enrolled in the study will smoke marijuana containing different
      concentrations of 2 different cannabinoids, THC and CBD. Both of these agents act on the
      brain's &quot;endocannabinoid system,&quot; which has been hypothesized to play a role in OCD. Neither
      compound is currently FDA-approved for treating OCD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale-Brown Obsessive-Compulsive Challenge Scale</measure>
    <time_frame>Weeks 0, 1, 2, 3</time_frame>
    <description>Change in the Yale-Brown Obsessive-Compulsive Challenge Scale</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>High THC/Low CBD Marijuana</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This condition involves the ingestion of marijuana with a high THC (5-10%) and low CBD (&lt;1%) content.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low THC/High CBD Marijuana</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This condition involves the ingestion of marijuana with a low THC (&lt;1%) and high CBD (&gt;10%) content.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No THC/No CBD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This condition involves the ingestion of a placebo control with no THC and no CBD content.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marijuana</intervention_name>
    <description>THC and CBD are &quot;cannabinoids&quot; which are found naturally in the marijuana plant. Both act on the brain's &quot;endocannabinoid system,&quot; which has been hypothesized to play a role in OCD.</description>
    <arm_group_label>High THC/Low CBD Marijuana</arm_group_label>
    <arm_group_label>Low THC/High CBD Marijuana</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control group, not receiving THC or CBD.</description>
    <arm_group_label>No THC/No CBD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21-55

          -  Physically healthy

          -  Diagnosed with OCD

          -  Current marijuana user

          -  Women of childbearing potential must be using an effective form of birth control

          -  Not currently taking psychotropic medications

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  History of any significant medical condition that may increase the risk of
             participation

          -  Females who are pregnant or nursing

          -  If female, not pregnant

          -  Current or lifetime history of psychiatric disorders other than OCD that may increase
             the risk of participation

          -  Current substance use disorder

          -  Severe depression or positive urine toxicology (other than THC) at screening, or any
             adverse reaction to a cannabinoid

          -  Patients who are seeking treatment for substance abuse

          -  Patients who are planning to begin a course of cognitive-behavioral therapy within 8
             weeks of beginning the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reilly Kayser, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marissa Raskin, B.S.</last_name>
    <phone>646-774-8062</phone>
    <email>Marissa.Raskin@nyspi.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Reilly Kayser, M.D.</last_name>
    <phone>646-774-6369</phone>
    <email>Reilly.Kayser@nyspi.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa Raskin, B.S.</last_name>
      <phone>646-774-8062</phone>
      <email>Marissa.Raskin@nyspi.columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCD</keyword>
  <keyword>Marijuana</keyword>
  <keyword>THC</keyword>
  <keyword>Cannabis</keyword>
  <keyword>CBD</keyword>
  <keyword>Cannabinoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

